PET/CT in cancer research: From preclinical to clinical applications

Contrast Media and Molecular Imaging

Volumn 5, Issue 4, 2010, Pages 190-200

  Del Vecchio, S ^a,b   Zannetti, A ^b   Fonti, R ^b   Iommelli, F ^b   Pizzuti, L M ^a   Lettieri, A ^b   Salvatore, M ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Cancer; PET CT; Translational research

Indexed keywords

3' FLUOROTHYMIDINE F 18; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEFITINIB; GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; PREDNISONE; RITUXIMAB; TRACER; TRASTUZUMAB; TUMOR MARKER; VINCRISTINE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER RESEARCH; CELL PROLIFERATION; COLON CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG MECHANISM; FIBROSARCOMA; FOLLICULAR LYMPHOMA; GENE TARGETING; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ANIMALS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77956139255     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.368     Document Type: Review

References (135)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 2008; 49 (suppl 2): 164S-179S.
3. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49 (suppl 2): 64S-80S.
4. 18F)fluorothymidine. Semin Nucl Med 2007; 37: 429-439.
5. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, Mattfeldt T, Liewald F, Reske SN, Neumaier B. 3-deoxy-3-((18)F) fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62: 3331-3334.
6. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallieres E, Wood DE. In vivo validation of 3′deoxy-3′- ((18)F)fluorothymidine (((18)F)FLT) as a proliferation imaging tracer in humans: correlation of ((18)F)FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8: 3315-3323.
7. 18F)FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imag 2003; 30: 1407-1412.
8. 18F-FDG. J Nucl Med 2003; 44: 1426-1431.
9. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA. Kinetic analysis of 3′-deoxy- 3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005; 46: 274-282.
10. Buck AK, Hetzel M, Schirrmeister H, Halter G, Moller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imag 2005; 32: 525-533.
11. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129: 393-401.
12. 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46: 400-404.
13. 18F)fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imag 2003; 30: 988-994.
14. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imag 2004; 31: 169-178.
15. 18F)-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681-2687.
16. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46: 1948-1958.
17. 18F)3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imag 2005; 32: 653-659.
18. 18F-FDG. J Nucl Med 2005; 46: 945-952.
19. 18F) fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005; 65: 10104-1012.
20. 18F)fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005; 65: 4202-4210.
21. 18F)fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-3798.
22. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, Mitchell F, Jackman AL, Aboagye EO. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006; 66: 8558-8564.
23. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, Vogg AT, Mattfeldt T, Neumaier B, Moller P, Reske SN. Early assessment of therapy response in malignant lymphoma with the thymidine analogue (18F)FLT. Eur J Nucl Med Mol Imag 2007; 34: 1775-1782. (Pubitemid 47599048)
24. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, zum Buschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imag Biol 2008; 10: 349-355.
25. 18F)fluorothymidine positron emission tomography. Cancer Res 2006; 66: 7621-7629.
26. 18F-fluorothymidine PET. J Nucl Med 2005; 46: 114-120.
27. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, Winkeler A. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-(F)-fluoro-L-thymidine ((F)FLT) positron emission tomography (PET). PLoS ONE 2008; 3: e3908.
28. Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, Golovko O, He Q, Workman P, Aboagye EO. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 2008; 7: 3112-3121.
29. 18F) fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25: 4714-4721.
30. 18F)fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007; 13: 3552-3558.
31. 18F)fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imag 2007; 34: 1339-1347.
32. 18F) 3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imag 2007; 34: 878-883.
33. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4: 956-965.
34. Cai W, Niu G, Chen X. Multimodality imaging of the HER-kinase axis in cancer. Eur J Nucl Med Mol Imag 2008; 35: 186-208.
35. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radio-isotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46: 1898-1906.
36. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imag 2007; 34: 850-858.
37. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009; 50: 123-131.
38. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, Carlsson J, Bergstrom M, Langstrom B, Tolmachev V. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46: 1881-1888.
39. Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, Gazit A, Levitzki A, Mishani E. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 2001; 28: 359-374.
40. Ortu G, Ben-David I, Rozen Y, Freedman NM, Chisin R, Levitzki A, Mishani E. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer 2002; 101: 360-370.
41. 124I-labeled small molecular tracer and positron emission tomography. Mol Imag Biol 2006; 8: 262-877.
42. Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, Shaul M, Levitzki A. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 2005; 48: 5337-5348.
43. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben David I, Levitzki A, Shaul M. Novel carbon-11 labeled 4-dimethylaminobut- 2-enoic acid (4-(phenylamino)-quinazoline-6-yl)-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 2004; 31: 469-476.
44. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, Levitzki A, Mishani E. Evaluation of radiolabeled ML04:a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 2007; 34: 55-70.
45. 11C)Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 2006; 16: 4102-4106.
46. 11C)-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69: 873-878.
47. 18F-Iressa and related molecular probes. J Label Compd Radiopharm 2005; 48: 829-843.
48. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of ((18)F)gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imag 2008; 35: 1089-1099.
49. 11C-PD153035 in humans. J Nucl Med 2009; 50: 303-308.
50. 11C-labeled PD153035 in rats without and with neuroblastoma implants. Life Sci 1999; 65: 165-174.
51. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007; 13: 527-534. (Pubitemid 350130347)
52. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? Eur J Cancer 2008; 44: 2781-2790.
53. Nielsen DL, Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35: 121-136.
54. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008; 44: 2806-2812.
55. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE, Adams GP. Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65: 1471-1478.
56. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65: 5907-5916.
57. 111In labeled Herceptin. Nucl Med Biol 2002; 29: 599-606.
58. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-706.
59. 18F-FDG PET. J Nucl Med 2006; 47: 793-796.
60. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14: 2999-3019.
61. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50: 417-25.
62. 18F-labeled protein scaffold molecules. J Nucl Med 2008; 49: 804-813.
63. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004; 64: 8009-8014.
64. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3- targeted magnetic resonance imaging. Nat Med 1998; 4: 623-626.
65. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007; 67: 1555-1562.
66. Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey ME, Sklenar J, Lindner JR. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108: 336-341.
67. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002; 62: 6146-6151.
68. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 1781-1785.
69. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 2004; 45: 1776-1783.
70. 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 2006; 66: 9673-9681.
71. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stocklin G, Schwaiger M. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999; 40: 1061-1071.
72. 18F)Galacto-RGD. PLoS Med 2:e 2005; 70.
73. 18F)Galacto- RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12: 3942-3949.
74. 18F)galacto- RGD positron emission tomography for imaging of alphav-beta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 6610-6616.
75. 18F-Galacto-RGD PET. J Nucl Med 2008; 49: 255-259.
76. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M. Imaging of alphavbeta3 expression by a bifunctional chimeric RGD peptide not cross-reacting with alphavbeta5. Clin Cancer Res 2009; 15: 5224-5233.
77. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005; 46: 1707-1718.
78. 18F-AH111585 in breast cancer patients. J Nucl Med 2008; 49: 879-886.
79. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imag 2004; 31: 1081-1089.
80. Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003; 63: 8563-8572. (Pubitemid 38064026)
81. Blankenberg FG. In vivo imaging of apoptosis. Cancer Biol Ther 2008; 7: 1525-1532.
82. 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-866.
83. Dekker B, Keen H, Lyons S, Disley L, Hastings D, Reader A, Ottewell P, Watson A, Zweit J. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol 2005; 32: 241-252.
84. 124I-annexin V and PET. Nucl Med Biol 2005; 32: 395-402.
85. Cauchon N, Langlois R, Rousseau JA, Tessier G, Cadorette J, Lecomte R, Hunting DJ, Pavan RA, Zeisler SK, van Lier JE. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imag 2007; 34: 247-258.
86. Gottlieb RA, Kitsis RN. Seeing death in the living. Nat Med 2001; 7: 1277-1278.
87. Brouckaert G, Kalai M, Krysko DV, Saelens X, Vercammen D, Ndlovu M, Haegeman G, D'Herde K, Vandenabeele P. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 2004; 15: 1089-1100.
88. Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung CM, Debouck C, Richardson S, Levy MA, DeWolf WE Jr, Keller PM, Tomaszek T, Head MS, Ryan MD, Haltiwanger RC, Liang PH, Janson CA, McDevitt PJ, Johanson K, Concha NO, Chan W, Abdel-Meguid SS, Badger AM, Lark MW, Nadeau DP, Suva LJ, Gowen M, Nuttall ME. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem 2000; 275: 16007-16014.
89. 18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 2009; 106: 16375-16380.
90. 11C)WC-98. Org Biomol Chem 2009; 7: 1337-1348.
91. 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imag 2007; 34: 2057-2065.
92. Aloya R, Shirvan A, Grimberg H, Reshef A, Levin G, Kidron D, Cohen A, Ziv I. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis 2006; 11: 2089-2101.
93. Zeng W, Yao ML, Townsend D, Kabalka G, Wall J, Le Puil M, Biggerstaff J, Miao W. Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis. Bioorg Med Chem Lett 2008; 18: 3573-3577.
94. Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, Ulysse LG, Friedman G, Antoni G, Ziv I. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med 2008; 49: 1520-1528.
95. 18F-ML-10 for early assessment of response of brain metastases to radiotherapy. J Nucl Med 2009; 50: 43.
96. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 2008; 27: 679-690.
97. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol 2003; 30: 119-125.
98. 11C)methyl-halo- CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002; 29: 761-770.
99. 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: radiosynthesis and initial small-animal PET studies. Appl Radiat Isot 2009; 67: 606-610.
100. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009; 14: 4575-4587.
101. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-136.
102. Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993; 53: 3198-3206.
103. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000; 60: 1546-1551.
104. Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997; 14: 1351-1359.
105. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62: 2390-2397. (Pubitemid 34411723)
106. Zannetti A, Del Vecchio S, Romanelli A, Scala S, Saviano M, Cali G, Stoppelli MP, Pedone C, Salvatore M. Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells. Biochem Pharmacol 2005; 70: 1277-1287.
107. Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006; 28: 831-839.
108. 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008; 14: 4758-4766.
109. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 1990; 50: 6757-6764.
110. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 2008; 18: 378-386.
111. Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)- beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 1997; 28: 443-449.
112. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-2634.
113. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 1853-1858.
114. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 9482-9487. (Pubitemid 37033954)
115. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999; 59: 5307-5314.
116. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008; 27: 631-644.
117. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 2007; 98: 1652-1658.
118. 64Cu-AMD3100 - a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem 2009; 17: 1486-1493.
119. 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
120. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imag 2009; 36 (suppl 1): S15-29.
121. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med 2008; 49 (suppl 2): 43S-63S.
122. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927-8930.
123. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 (suppl 2): 24S-42S.
124. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008; 49: 938-955.
125. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.
126. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009; 50 (suppl): 21S-30S.
127. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
128. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (suppl 1): 122S-a50S.
129. Vriens D, de Geus-Oei LF, van der Graaf WTA, Oyen WJG. Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imag 2009; 53: 224-244.
130. Chuang HH, Macapinlac HA. The evolving role of PET-CT in the management of esophageal cancer. Q J Nucl Med Mol Imag 2009; 53: 201-209.
131. 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 2009; 50 (suppl): 31S-42S.
132. Pons F, Duch J, Fuster D. Breast cancer therapy: the role of PET-CT in decision making. Q J Nucl Med Mol Imag 2009; 53: 210-223.
133. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
134. Delso G, Ziegler S. PET/MRI system design. Eur J Nucl Med Mol Imag 2009; 36 (suppl 1): S86-92.
135. Pichler BJ, Wehrl HF, Judenhofer MS. Latest advances in molecular imaging instrumentation. J Nucl Med 2008; 49 (suppl 2): 5S-23S.